THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth announced today that it will share findings demonstrating the clinical value of next-generation sequencing (NGS) in newly diagnosed breast cancer patients at this year’s San Antonio Breast Cancer Symposium. Using retrospective data from HER2-positive breast cancer patients, the two abstracts accepted for presentation will show how sequencing at diagnosis would have led to safer, more effective treatments for patients nonresponsive to anti-HER2 therapies.
Help employers find you! Check out all the jobs and post your resume.
